tetano
Editor, Senior Moderator
Cell
. 2022 Apr 27;S0092-8674(22)00527-X.
doi: 10.1016/j.cell.2022.04.029. Online ahead of print.
Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Kun Xu[SUP] 1 [/SUP], Ping Gao[SUP] 2 [/SUP], Sheng Liu[SUP] 3 [/SUP], Shuaiyao Lu[SUP] 4 [/SUP], Wenwen Lei[SUP] 5 [/SUP], Tianyi Zheng[SUP] 6 [/SUP], Xueyuan Liu[SUP] 7 [/SUP], Yufeng Xie[SUP] 8 [/SUP], Zhennan Zhao[SUP] 2 [/SUP], Shuxin Guo[SUP] 9 [/SUP], Cong Tang[SUP] 4 [/SUP], Yun Yang[SUP] 4 [/SUP], Wenhai Yu[SUP] 4 [/SUP], Junbin Wang[SUP] 4 [/SUP], Yanan Zhou[SUP] 4 [/SUP], Qing Huang[SUP] 4 [/SUP], Chuanyu Liu[SUP] 10 [/SUP], Yaling An[SUP] 11 [/SUP], Rong Zhang[SUP] 10 [/SUP], Yuxuan Han[SUP] 11 [/SUP], Minrun Duan[SUP] 12 [/SUP], Shaofeng Wang[SUP] 2 [/SUP], Chenxi Yang[SUP] 2 [/SUP], Changwei Wu[SUP] 13 [/SUP], Xiaoya Liu[SUP] 13 [/SUP], Guangbiao She[SUP] 13 [/SUP], Yan Liu[SUP] 14 [/SUP], Xin Zhao[SUP] 15 [/SUP], Ke Xu[SUP] 5 [/SUP], Jianxun Qi[SUP] 15 [/SUP], Guizhen Wu[SUP] 16 [/SUP], Xiaozhong Peng[SUP] 17 [/SUP], Lianpan Dai[SUP] 18 [/SUP], Peiyi Wang[SUP] 19 [/SUP], George F Gao[SUP] 20 [/SUP]
Affiliations
Abstract
Breakthrough infections by SARS-CoV-2 variants become the global challenge for pandemic control. Previously, we developed the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2. Here, we developed a chimeric RBD-dimer vaccine approach to adapt SARS-CoV-2 variants. A prototype-Beta chimeric RBD-dimer was first designed to adapt the resistant Beta variant. Compared with its homotypic forms, the chimeric vaccine elicited broader sera neutralization of variants and conferred better protection in mice. The protection of the chimeric vaccine was further verified in macaques. This approach was generalized to develop Delta-Omicron chimeric RBD-dimer to adapt the currently prevalent variants. Again, the chimeric vaccine elicited broader sera neutralization of SARS-CoV-2 variants and conferred better protection against challenge by either Delta or Omicron SARS-CoV-2 in mice. The chimeric approach is applicable for rapid updating of immunogens, and our data supported the use of variant-adapted multivalent vaccine against circulating and emerging variants.
Keywords: COVID19 vaccine; Delta variant; Omicron variant; RBD; SARS-CoV-2; VOC; immunogen structure; receptor-binding domain; vaccine protection; variant of concern.
. 2022 Apr 27;S0092-8674(22)00527-X.
doi: 10.1016/j.cell.2022.04.029. Online ahead of print.
Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Kun Xu[SUP] 1 [/SUP], Ping Gao[SUP] 2 [/SUP], Sheng Liu[SUP] 3 [/SUP], Shuaiyao Lu[SUP] 4 [/SUP], Wenwen Lei[SUP] 5 [/SUP], Tianyi Zheng[SUP] 6 [/SUP], Xueyuan Liu[SUP] 7 [/SUP], Yufeng Xie[SUP] 8 [/SUP], Zhennan Zhao[SUP] 2 [/SUP], Shuxin Guo[SUP] 9 [/SUP], Cong Tang[SUP] 4 [/SUP], Yun Yang[SUP] 4 [/SUP], Wenhai Yu[SUP] 4 [/SUP], Junbin Wang[SUP] 4 [/SUP], Yanan Zhou[SUP] 4 [/SUP], Qing Huang[SUP] 4 [/SUP], Chuanyu Liu[SUP] 10 [/SUP], Yaling An[SUP] 11 [/SUP], Rong Zhang[SUP] 10 [/SUP], Yuxuan Han[SUP] 11 [/SUP], Minrun Duan[SUP] 12 [/SUP], Shaofeng Wang[SUP] 2 [/SUP], Chenxi Yang[SUP] 2 [/SUP], Changwei Wu[SUP] 13 [/SUP], Xiaoya Liu[SUP] 13 [/SUP], Guangbiao She[SUP] 13 [/SUP], Yan Liu[SUP] 14 [/SUP], Xin Zhao[SUP] 15 [/SUP], Ke Xu[SUP] 5 [/SUP], Jianxun Qi[SUP] 15 [/SUP], Guizhen Wu[SUP] 16 [/SUP], Xiaozhong Peng[SUP] 17 [/SUP], Lianpan Dai[SUP] 18 [/SUP], Peiyi Wang[SUP] 19 [/SUP], George F Gao[SUP] 20 [/SUP]
Affiliations
- PMID: 35568034
- PMCID: PMC9042943
- DOI: 10.1016/j.cell.2022.04.029
Abstract
Breakthrough infections by SARS-CoV-2 variants become the global challenge for pandemic control. Previously, we developed the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2. Here, we developed a chimeric RBD-dimer vaccine approach to adapt SARS-CoV-2 variants. A prototype-Beta chimeric RBD-dimer was first designed to adapt the resistant Beta variant. Compared with its homotypic forms, the chimeric vaccine elicited broader sera neutralization of variants and conferred better protection in mice. The protection of the chimeric vaccine was further verified in macaques. This approach was generalized to develop Delta-Omicron chimeric RBD-dimer to adapt the currently prevalent variants. Again, the chimeric vaccine elicited broader sera neutralization of SARS-CoV-2 variants and conferred better protection against challenge by either Delta or Omicron SARS-CoV-2 in mice. The chimeric approach is applicable for rapid updating of immunogens, and our data supported the use of variant-adapted multivalent vaccine against circulating and emerging variants.
Keywords: COVID19 vaccine; Delta variant; Omicron variant; RBD; SARS-CoV-2; VOC; immunogen structure; receptor-binding domain; vaccine protection; variant of concern.